Effect of Metformin Plus Tyrosine Kinase Inhibitors Co
Inhibitors Alone in Patients With Epidermal Growth Fa
Adenocarcinoma

JAMA Oncology

5, e192553

DOI: 10.1001/jamaoncol.2019.2553

Citation Report

#	Article	IF	Citations
1	Mesothelial Cell HIF1Î± Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Reports, 2019, 29, 4086-4098.e6.	6.4	26
2	Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?. Clinical Cancer Research, 2020, 26, 523-525.	7.0	8
3	The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials. International Journal of Medical Sciences, 2020, 17, 2551-2560.	2.5	8
4	Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma. Journal of Cancer, 2020, 11, 6437-6444.	2.5	10
5	Traitement des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s EGFR : quels inhibiteurs ? Quelles sÃ©quences thÃ©rapeutiques ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S195-2S211.	0.0	2
6	Mitochondrial Metabolism as a Target for Cancer Therapy. Cell Metabolism, 2020, 32, 341-352.	16.2	323
7	GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin. Frontiers in Endocrinology, 2020, 11, 581839.	3.5	20
8	Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Frontiers in Immunology, 2020, 11, 573326.	4.8	50
9	Circulating Insulin-Like Growth Factor-1 and Risk of Total and 19 Site-Specific Cancers: Cohort Study Analyses from the UK Biobank. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2332-2342.	2.5	22
10	Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Advanced Drug Delivery Reviews, 2020, 159, 245-293.	13.7	316
11	X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis. Clinical Cancer Research, 2020, 26, 5567-5578.	7.0	33
12	Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules, 2020, 25, 4831.	3.8	69
13	Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer, 2020, 20, 829.	2.6	11
14	Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota. Open Forum Infectious Diseases, 2020, 7, ofaa338.	0.9	33
15	Systemic therapy for adrenocortical carcinoma: a review. AME Medical Journal, 0, 5, 5-5.	0.4	5
16	Metformin and everolimus in neuroendocrine tumours: A synergic effect?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 954-960.	1.5	5
17	Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. Cancers, 2020, 12, 1587.	3.7	24
18	Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies. Cancers, 2020, 12, 1475.	3.7	69

#	Article	IF	Citations
19	A Robust Signature Based on Autophagy-Associated LncRNAs for Predicting Prognosis in Lung Adenocarcinoma. BioMed Research International, 2020, 2020, 1-13.	1.9	12
20	Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Research and Therapy, 2020, 17, 10.	1.7	43
21	An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. Theranostics, 2020, 10, 3083-3098.	10.0	36
22	Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 782.	7.1	1
23	Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancerâ€”Reply. JAMA Oncology, 2020, 6, 782.	7.1	1
24	Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. , 2020, 8, e000289.		51
25	Repression of LKB1 by miR-17â^¼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment. Cell Reports Medicine, 2020, 1, 100014.	6.5	16
26	Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. Cells, 2020, 9, 428.	4.1	111
27	Metformin and Exercise in Cancer: Better Together. JNCI Cancer Spectrum, 2020, 4, pkz097.	2.9	1
28	Loss of Rb1 Enhances Glycolytic Metabolism in Kras-Driven Lung Tumors In Vivo. Cancers, 2020, 12, 237.	3.7	12
29	In Vitro Dissolution and In Vivo Bioequivalence Evaluation of Two Metformin Extendedâ€Release Tablets. Clinical Pharmacology in Drug Development, 2021, 10, 414-419.	1.6	7
30	Metformin use and lung cancer survival: a population-based study in Norway. British Journal of Cancer, 2021, 124, 1018-1025.	6.4	15
31	Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer, 2021, 151, 8-15.	2.0	23
32	Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 73-76.	1.1	2
33	Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor. Archives of Oral Biology, 2021, 121, 104971.	1.8	3
34	Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer. Cellular Oncology (Dordrecht), 2021, 44, 1-18.	4.4	18
35	Shining a light on metabolic vulnerabilities in non-small cell lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188462.	7.4	9
36	The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. Journal of Thoracic Oncology, 2021, 16, 76-88.	1.1	50

#	Article	IF	Citations
37	Targeting cancer-promoting inflammation â€" have anti-inflammatory therapies come of age?. Nature Reviews Clinical Oncology, 2021, 18, 261-279.	27.6	171
38	The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Oncology, 2021, 99, 555-561.	1.9	13
39	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clinical and Research Reports, 2021, 2, 100107.	1.1	15
40	Repurposing approved drugs for cancer therapy. British Medical Bulletin, 2021, 137, 13-27.	6.9	28
41	Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer. Oncoscience, 2021, 8, 1-13.	2.2	1
42	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptorâ€"Positive Advanced Breast Cancer (EVERMET). Clinical Cancer Research, 2021, 27, 3443-3455.	7.0	4
43	Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancerâ€"an option for overcoming EGFR-TKI resistance. Translational Lung Cancer Research, 2021, 10, 1277-1291.	2.8	15
44	Drug Repurposing in Oncology: Current Evidence and Future Direction. Current Medicinal Chemistry, 2021, 28, 2175-2194.	2.4	6
45	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. Current Medicinal Chemistry, 2021, 28, 2114-2136.	2.4	6
46	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. Cancers, 2021, 13, 2474.	3.7	13
47	Smart Stimuli-Responsive and Mitochondria Targeting Delivery in Cancer Therapy. International Journal of Nanomedicine, 2021, Volume 16, 4117-4146.	6.7	14
49	Drug repurposing strategies in the development of potential antifungal agents. Applied Microbiology and Biotechnology, 2021, 105, 5259-5279.	3.6	27
50	Metformin Adjunct With Antineoplastic Agents for the Treatment of Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies. Frontiers in Pharmacology, 2021, 12, 639016.	3.5	15
51	Metformin, Macrophage Dysfunction and Atherosclerosis. Frontiers in Immunology, 2021, 12, 682853.	4.8	59
52	Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2021, 12, 676399.	3.5	5
53	Associations of aspirin, statins and metformin with lung cancer risk and related mortality. Breathe, 2021, 17, 200325.	1.3	1
54	Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. , 2021, 9, e002773.		28
55	The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2819-2836.	2.5	6

#	Article	IF	Citations
56	Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Pharmacological Research, 2021, 170, 105701.	7.1	15
57	Lessons from Cancer Metabolism for Pulmonary Arterial Hypertension and Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 134-145.	2.9	9
58	Autophagy Modulators in Cancer: Focus on Cancer Treatment. Life, 2021, 11, 839.	2.4	13
59	Therapeutic Repurposing of Biguanides in Cancer. Trends in Cancer, 2021, 7, 714-730.	7.4	32
60	Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1324.	7.1	53
61	Diabetes And Lung Cancer; A Sweet And Sour Relationship. Current Respiratory Medicine Reviews, 2021, 17, .	0.2	0
62	Metformin: current clinical applications in nondiabetic patients with cancer. Aging, 2020, 12, 3993-4009.	3.1	52
63	The potential adjunctive benefit of adding metformin to standard treatment in inoperable cancer patients: a meta-analysis of randomized controlled trials. Annals of Translational Medicine, 2020, 8, 1404-1404.	1.7	10
64	Off-Label Medication: From a Simple Concept to Complex Practical Aspects. International Journal of Environmental Research and Public Health, 2021, 18, 10447.	2.6	24
65	Repurposing of Anti-diabetic Drug in Cancer Prevention. Novel Approaches in Cancer Study, 2020, 4, .	0.2	0
66	Animal models and inÂvivo investigations for drug repurposing in lung cancer. , 2020, , 273-293.		1
68	Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug. Anticancer Research, 2021, 41, 5913-5918.	1.1	11
69	Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma. JAMA Oncology, 2022, 8, 477.	7.1	13
70	Advances in metforminâ€‘based metabolic therapy for nonâ€‘small cell lung cancer (Review). Oncology Reports, 2022, 47, .	2.6	15
71	Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. Theranostics, 2022, 12, 2722-2740.	10.0	45
72	The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China. Frontiers in Pharmacology, 2022, 13, 862640.	3.5	0
73	The effect of metformin on bladder cancer incidence and outcomes â€“a systematic review and meta-analysis. Bladder Cancer, 2022, , 1-18.	0.4	1
74	Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelialâ€“Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals, 2022, 15, 381.	3.8	6

#	Article	IF	Citations
75	Classification of atypical EGFR mutations in non-small cell lung cancer. Annals of Oncology, 2022, , .	1.2	0
76	Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia. Pharmaceuticals, 2022, 15, 312.	3.8	20
77	Metformin induces myeloma cells necrosis and apoptosis and it is considered for therapeutic use. Journal of Chemotherapy, 2023, 35, 131-141.	1.5	10
79	Uniting Latin America Through Research: How Regional Research Can Strengthen Local Policies, Networking, and Outcomes for Patients With Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 463-469.	3.8	4
80	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 2613.	3.7	8
81	Metformin and Cancer, an Ambiguanidous Relationship. Pharmaceuticals, 2022, 15, 626.	3.8	22
82	Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. Pharmaceuticals, 2022, 15, 786.	3.8	8
83	First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2022, 40, 1001-1010.	2.6	14
84	Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. Journal of Hematology and Oncology, 2022, 15, .	17.0	53
85	A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study. EClinicalMedicine, 2022, 51, 101541.	7.1	12
86	The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. Cellular and Molecular Biology Letters, 2022, 27, .	7.0	12
87	Areneâ€Ruthenium(II)/Osmium(II) Complexes Potentiate the Anticancer Efficacy of Metformin via Glucose Metabolism Reprogramming. Angewandte Chemie - International Edition, 2022, 61, .	13.8	5
88	Areneâ€Ruthenium(II)/Osmium(II) Complexes Potentiate the Anticancer Efficacy of Metformin via Glucose Metabolism Reprogramming. Angewandte Chemie, 0, , .	2.0	0
89	A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer. Clinical Cancer Research, 2022, 28, 5263-5271.	7.0	10
90	The role of metformin in the treatment of non-small cell lung cancer. Zdravstvena Zastita, 2022, 51, 32-53.	0.2	0
91	The Anticancer Effect of Metformin Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Oncology and Therapy, 2022, 10, 363-375.	2.6	3
92	Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials. BMC Medicine, 2022, 20, .	5.5	12
93	NNMTâ€DNMT1 Axis is Essential for Maintaining Cancer Cell Sensitivity to Oxidative Phosphorylation Inhibition. Advanced Science, 2023, 10, .	11.2	9

#	Article	IF	Citations
94	Metformin: A Promising Antidiabetic Medication for Cancer Treatment. Current Drug Targets, 2023, 24, 41-54.	2.1	6
95	Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review). Oncology Reports, 2022, 49, .	2.6	4
96	Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?. Frontiers in Oncology, 0, 12, .	2.8	0
97	Association of metformin use and survival in patients with cutaneous melanoma and diabetes. British Journal of Dermatology, 2023, 188, 32-40.	1.5	4
98	Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. Journal of Translational Medicine, 2022, 20, .	4.4	4
99	Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	7
100	A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition. International Journal of Molecular Sciences, 2023, 24, 4331.	4.1	1
101	Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?. British Journal of Cancer, 2023, 128, 958-966.	6.4	28
102	Mechanisms of ageing: growth hormone, dietary restriction, and metformin. Lancet Diabetes and Endocrinology,the, 2023, 11, 261-281.	11.4	5
103	Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents. Frontiers in Pharmacology, 0, 14, .	3.5	0
104	High Expression of COA6 Is Related to Unfavorable Prognosis and Enhanced Oxidative Phosphorylation in Lung Adenocarcinoma. International Journal of Molecular Sciences, 2023, 24, 5705.	4.1	4
105	Metabolic reprogramming in cancer: Mechanisms and therapeutics. MedComm, 2023, 4, .	7.2	18
106	A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG). , 2023, 40, .		0
107	Metformin may be a viable adjunctive therapeutic option to potentially enhance immune reconstitution in HIV-positive immunological non-responders. Chinese Medical Journal, 0, Publish Ahead of Print, .	2.3	2
108	Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis. Journal of Research in Medical Sciences, 2023, 28, 45.	0.9	0
109	Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial. , 2023, 1, 119-124.		0
110	Mitochondrial immune regulation and anti-tumor immunotherapy strategies targeting mitochondria. Cancer Letters, 2023, 564, 216223.	7.2	7
111	JAC4 Inhibits EGFR-Driven Lung Adenocarcinoma Growth and Metastasis through CTBP1-Mediated JWA/AMPK/NEDD4L/EGFR Axis. International Journal of Molecular Sciences, 2023, 24, 8794.	4.1	1

#	Article	IF	Citations
112	Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes. Clinical and Translational Oncology, 2024, 26, 836-850.	2.4	0
113	Multifaceted roles of mitochondrial dysfunction in diseases: from powerhouses to saboteurs. Archives of Pharmacal Research, 2023, 46, 723-743.	6.3	0
114	The Effects of a Curcumin Derivative and Osimertinib on Fatty Acyl Metabolism and Mitochondrial Functions in HCC827 Cells and Tumors. International Journal of Molecular Sciences, 2023, 24, 12190.	4.1	0
115	Current status and frontier tracking of clinical trials on Metformin for cancer treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 16931-16946.	2.5	1
116	Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology, 0, 13, .	2.8	1
117	Crucial Metabolic Networks: Cancer Progression. , 2023, , 1-16.		0
118	Metformin: AÂpotential adjunct for treatment of systemic mastocytosis. , 2024, 3, 100186.		0
119	Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma. Cancer Letters, 2024, 581, 216497.	7.2	4
120	Recent advances in anticancer drug discovery: A review. International Journal of Pharmaceutical Chemistry and Analysis, 2023, 10, 229-236.	0.2	0
121	Mitochondrion: Main organelle in orchestrating cancer escape from chemotherapy. Cancer Reports, 2024, 7, .	1.4	0
122	Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACSâ€010759. Molecular Oncology, 0, , .	4.6	1
123	Research Status of Anti-Aging Drugs in Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2024, 14, 1490-1500.	0.0	0
124	Cancer biology in diabetes update: Focusing on antidiabetic drugs. Journal of Diabetes Investigation, 2024, 15, 525-540.	2.4	0
125	Cardiovascular/antiâ€inflammatory drugs repurposed for treating or preventing cancer: A systematic review and metaâ€analysis of randomized trials. Cancer Medicine, 2024, 13, .	2.8	0